AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.
[More]
Lexicon Pharmaceuticals, Inc. announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial.
[More]
Archimedes, Inc., a healthcare modeling and analytics company, announced today that it has begun collaborating with the United States Department of Health and Human Services and Centers for Medicare & Medicaid Services to provide unprecedented access to synthetic CMS claims data.
[More]
Individuals with diabetes may reduce their risk for developing nephropathy if they minimize their exposure to persistent organic pollutants, suggest researchers.
[More]
Laparoscopic radical nephrectomy is an effective treatment approach for individuals with renal cell carcinoma who have larger or more advanced renal masses, report researchers.
[More]
Individuals with Type 1 diabetes should keep good control of their blood sugar levels and blood pressure to reduce their risk for developing nephropathy, say researchers.
[More]
CellAegis Devices, Inc., announced today that it has received an Investigational Testing Approval from Health Canada that allows the initiation of clinical testing in Canada of the Company's autoRIC Device for Chronic Remote Ischemic Conditioning (CRIC).
[More]
CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen, immune globulin intravenous [human].
[More]
UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).
[More]
The xanthine oxidase inhibitor allopurinol appears to be beneficial in preventing cardiovascular morbidity and all-cause mortality in patients with hypertensive nephropathy, show findings from a Japanese study.
[More]
Researchers have identified the main risk factors for renal functional abnormalities in children with high-grade vesicoureteral reflux.
[More]
Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease.
[More]
Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.
[More]
The results of a pioneering UK-wide clinical trial that compared treatments for patients with a common type of kidney disease has found one to be significantly more effective. The results of the study, published online in The Lancet, will be recommended to clinicians worldwide as the most effective approach to treating the condition.
[More]
Pharmalink AB, a Swedish specialty pharma company, today announces it has initiated a Phase IIb study with Nefecon (Nefigan) in patients with primary IgA nephropathy at risk of developing end-stage renal disease.
[More]
University of Texas Medical Branch at Galveston researchers have discovered that the commonly used antidepressant drug paroxetine could also become a therapy for the vascular complications of diabetes.
[More]
Swift Charities, the charitable arm of Swift Transportation, today donated $15,262 to The Waylon Jennings Fund for Diabetes Research at the Translational Genomics Research Institute (TGen).
[More]
NOXXON Pharma today announced the treatment of the first patients in a Phase IIa clinical trial of its anti-hepcidin Spiegelmer NOX-H94 to treat anemia associated with chronic disease.
[More]
Renal scarring associated with vesicoureteral reflux is a significant risk factor for developing hypertension, shows a study of pediatric patients.
[More]
Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, such as cardiac disease and kidney disease, according to a new study by rheumatology researchers at Hospital for Special Surgery. The study appears online ahead of print, in the journal Arthritis and Rheumatism.
[More]